Marker Identifies Breast Cancer Patients Likely to Respond to Tamoxifen

ER positive breast cancer patients whose tumors have active protein Stat5 have increased likelihood of responding to anti-estrogen therapy PHILADELPHIA—Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy. The research appears …


Prolactin Blocks Oncogene Associated with Poor Prognosis in Breast Cancer

Researchers from the Kimmel Cancer Center at Jefferson have found a mechanism by which a hormone responsible for milk production blocks an oncogene that makes breast cancer more aggressive. Publishing in the journal Cancer Research, the researchers discovered that prolactin, a pituitary hormone that normally stimulates breast development and milk production, in fact reduces levels …


Jefferson’s Kimmel Cancer Center Researchers Receive $6.7 million Grant from Susan G. Komen for the Cure

Researchers from the Kimmel Cancer Center at Jefferson were awarded a Susan G. Komen for the Cure Promise Grant of almost $6.7 million for five years for continued breast cancer research. The project represents a multidisciplinary team of scientists from a consortium that also includes Walter Reed Army Medical Center and DecisionQ Inc. in Washington …


Jefferson Breast Cancer Researcher to Receive PA Income Tax Check-Off Grant

Hallgeir Rui, M.D., Ph.D, a professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University and Jefferson’s Kimmel Cancer Center, is one of three recipients of the Income Tax Check-Off for Breast & Cervical Cancer Research grants this year. The $50,000 award will be used to conduct research to understand what causes the …